---
title: "Weekly Recap | Adma Biologics +3.62%, most brokers rate it buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300846359.md"
description: "Adma Biologics (ADMA) rose 3.62% this week to close at $9.72, while the S&P 500 slipped 0.27%, leaving the stock ahead of the benchmark by about 3.89 percentage points. The move was a fade: Monday (Sep 28) opened soft and rallied to $10.12, Tuesday through Thursday stayed in a narrow $9.93-$10.03 range, and Friday (Oct 2) tagged the week’s high of $10.285 before retreating to $9.72. Average daily volume of around 3."
datetime: "2026-10-03T06:17:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300846359.md)
  - [en](https://longbridge.com/en/news/300846359.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300846359.md)
generator: "portal-rs"
---

# Weekly Recap | Adma Biologics +3.62%, most brokers rate it buy

## The Week

Adma Biologics (ADMA) rose 3.62% this week to close at $9.72, while the S&P 500 slipped 0.27%, leaving the stock ahead of the benchmark by about 3.89 percentage points. The move was a fade: Monday (Sep 28) opened soft and rallied to $10.12, Tuesday through Thursday stayed in a narrow $9.93-$10.03 range, and Friday (Oct 2) tagged the week’s high of $10.285 before retreating to $9.72. Average daily volume of around 3.3m shares ran 35% above its recent median, with no company-specific catalyst and price action tracking sector sentiment.

## Analyst Ratings

Four brokers cover the stock: two rate it buy, one overweight and one hold, with no underweight or sell ratings. The consensus recommendation is buy, with a consensus target of $17, about 74.9% above the $9.72 close. Targets range from $12 to $21, nearly a two-fold spread that points to wide disagreement. Within biotech, the stock ranks 312 out of 507, putting it in the middle-to-lower band.

## The Week Ahead

Macro data dominates: Monday (Oct 5) brings the S&P Global services PMI final and ISM non-manufacturing PMI, Tuesday (Oct 6) the US trade balance, and Wednesday (Oct 7) EIA weekly crude and Cushing inventory reports. If this week’s gene-editing sentiment spills over, plasma-focused names like ADMA could feel the rotation. No company-specific events are on the calendar.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [ADMA.US](https://longbridge.com/en/quote/ADMA.US.md)

## Related News & Research

- [ADMA Biologics Study Shows Optimized IVIG Process Removes Impurities Linked to Thrombosis Risk](https://longbridge.com/en/news/301967470.md)
- [WINTON GROUP Ltd Lowers Stock Holdings in ADMA Biologics Inc $ADMA](https://longbridge.com/en/news/299519394.md)
- [AI fever ignites a boom in thematic ETFs as fund managers hunt for their next big hit](https://longbridge.com/en/news/302963080.md)
- [9,987 Shares of Linde PLC $LIN Bought by Family Capital Trust Co](https://longbridge.com/en/news/302957321.md)
- [Zoom Poised for Long-Term Value Creation as Analyst Highlights AI-Driven Platform Evolution and Credible FY2030 Profit Targets](https://longbridge.com/en/news/302949392.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**